DIPROSONE Cream and Ointment are indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Description

DIPROSONE Cream/Ointment contain in each gram betamethasone dipropionate, a synthetic corticosteroid, equivalent to 0.5 mg (0.05%) of betamethasone, in a lipid-free, paraben-free vehicle.

Inactive ingredients in DIPROSONE Cream:

Inactive ingredients in DIPROSONE Ointment:

ACTIONS

DIPROSONE Cream and Ointment are effective because of their anti-inflammatory, antipruritic and Vaso-constrictive actions. they demonstrate these activities in a sustained- manner, thereby permitting twice-a-day or in some cases, once-a-day application.

DOSAGE AND ADMINISTRATION

A thin film of DIPROSONE Cream or Ointment should be applied to cover completely the affected area once or twice daily, morning and night.

ADVERSE REACTIONS

The following local adverse reactions have been infrequently reported with the use of topical corticosteroids especially under occlusive dressings:

CONTRAINDICATIONS

DIPROSONE Cream and Ointment are contraindicated in those patients with a history of sensitivity reactions to any of its components.

PRECAUTIONS

If irritation or sensitization develops with the use of DIPROSONE Cream or Ointment, treatment should be discontinued and appropriate therapy instituted.

In the presence of an infection, an appropriate antifungal or antibacterial agent should be administered. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been controlled adequately.

Any of the side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children. Systemic absorption of topical corticosteroids will be increased if extensive skin surfaces are treated or if occlusive technique is used. Suitable precautions should be taken under these conditions or when long-term use is anticipated, particularly in infants and children.

DIPROSONE Cream and Ointment are not for ophthalmic use.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility than mature patients to topical corticosteroid induced HPA axis suppression and to exogenous corticosteroid effects because of greater absorption due to a larger skin surface area to body weight ratio.

HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids.

Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include a bulging fontanelle, headaches and bilateral papilledema.

USE DURING PREGNANCY AND IN NURSING WOMEN

Since safety of topical corticosteroid use in pregnant women has not been established, drugs of this class should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus…. Drugs of this class should not be used extensively in large amounts or for prolonged periods of time in pregnant patents.

 Since it is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

OVERDOSAGE

Symptoms: excessive or prolonged use of topical corticosteroids can suppress pituitary-adrenal function, resulting in secondary adrenal insufficiency and produce manifestations of hypercorticism, including Cushing’s disease.

Treatment: Appropriate symptomatic treatment is indicated. Acute hyper corticoid symptoms are usually reversible. Treat electrolyte imbalance, if necessary. In case of chronic toxicity, slow withdrawal of corticosteroids is advised

Diprosone Cream

DIPROSONE CREAM & OINT PATIENT INFORMATION LEAFLET

Diprosone Arabic Information

حقوق النشر: “All rights reserved (c)” تواصل معنا عبر تطبيق واتس_آب أو عبر نموذج التواصل..التحديث و الإضافة والتعديل: تواصل معنا، إذا كنت تعرف أي معلومات، تحديثات، إضافات أو تعديلات يمكن إضافتها إلى هذة الصفحة، عبر تطبيق الواتس آب أو البريد الإلكتروني([email protected]) أو عبر نموذج التواصل أو اكتب تعليق في أسفل الصفحة .. #betamethasone dipropionate علامات مرجعية: #D07AC ، #الستيرويدات_القشرية_الجلدية_القوية_(المجموعة_الثالثة)، #Corticosteroids, potent (group III)